title: Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML.
abstract: KDM1A/LSD1, a histone H3K4/K9 demethylase and epigenetic regulator with roles in both gene activation and repression, has increased expression in multiple cancer types. Harris et al., in this issue of Cancer Cell, and Schenk et al. show that KDM1A may be a viable therapeutic target in treating AML.
authors.affiliation: Oncology Institute, Loyola University Chicago, Maywood, IL 60153, USA.
authors.forename: Alyson A
authors.initials: AA
authors.lastname: Lokken
authors.forename: Nancy J
authors.initials: NJ
authors.lastname: Zeleznik-Le